Synthesis and evaluation of N-nicotinoyl-2-{2-(2-methyl-5-nitroimidazol-1- yl)ethyloxy}-D,L-glycine as a colon-specific prodrug of metronidazole

Journal of Pharmaceutical Sciences

Volumn 98, Issue 11, 2009, Pages 4161-4169

  Kim, Duksoo ^a   Hong, Sungchae ^a   Jung, Sunhwa ^a   Jung, Yunjin ^a   Kim, Young Mi ^a  

^a Pusan National University   (South Korea)

Author keywords

Colon specific prodrug; Colonic delivery; Luminal amoebiasis; Metronidazole

Indexed keywords

GLYCINE DERIVATIVE; METRONIDAZOLE; N NICOTINOYL 2[2(2 METHYL 5 NITROIMIDAZOL 1 YL)ETHYLOXY]D,L GLYCINE; NITROREDUCTASE; PRODRUG; UNCLASSIFIED DRUG;

AMEBIASIS; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG METABOLISM; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; LARGE INTESTINE; MALE; NONHUMAN; PARTITION COEFFICIENT; PROTOZOAL INFECTION; RAT; SMALL INTESTINE;

EID: 70349642683     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21720     Document Type: Article

References (25)

1. Petri WA Jr. 2003. Therapy of intestinal protozoa. Trends Parasitol 19:523-526.
2. Stanley SL Jr. 2003. Amoebiasis. Lancet 361:1025-1034.
3. Freeman CD, Klutman NE, Lamp KC. 1997. Metronidazole. A therapeutic review and update. Drugs 54:679-708.
4. Ludlum DB, Colinas RJ, Kirk MC, Mehta JR. 1988. Reaction of reduced metronidazole with guanosine to form an unstable adduct. Carcinogenesis 9:593-596.
5. Leitsch D, Kolarich D, Wilson IB, Altmann F, Duchene M. 2007. Nitroimidazole action in Entamoeba histolytica: A central role for thioredoxin reductase. PLoS Biol 5:e211. (Pubitemid 47328284)
6. Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH. 1992. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 23:328-364.
7. Lamp KC, Freeman CD, Klutman NE, Lacy MK. 1999. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 36:353-373.
8. Kapoor K, Chandra M, Nag D, Paliwal JK, Gupta RC, Saxena RC. 1999. Evaluation of metronidazole toxicity: A prospective study. Int J Clin Pharmacol Res 19:83-88. (Pubitemid 30162679)
9. Shareef MA, Khar RK, Ahuja A, Ahmad FJ, Raghava S. 2003. Colonic drug delivery: An updated review. AAPS PharmSci 5:E17. (Pubitemid 38097483)
10. Rubinstein A. 1995. Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carrier Syst 12:101-149.
11. Kinget R, Kalala W, Vervoort L, van den Mooter G. 1998. Colonic drug targeting. J Drug Target 6:129-149.
12. Sinha VR, Kumria R. 2001. Polysaccharides in colon-specific drug delivery. Int J Pharm 224:19-38.
13. Sinha VR, Kumria R. 2001. Colonic drug delivery: Prodrug approach. Pharm Res 18:557-564. (Pubitemid 32595781)
14. Mundargi RC, Patil SA, Agnihotri SA, Aminabhavi TM. 2007. Development of polysaccharide-based colon targeted drug delivery systems for the treatment of amoebiasis. Drug Dev Ind Pharm 33:255-264.
15. Krishnaiah YS, Bhaskar Reddy PR, Satyanarayana V, Karthikeyan RS. 2002. Studies on the development of oral colon targeted drug delivery systems for metronidazole in the treatment of amoebiasis. Int J Pharm 236:43-55. (Pubitemid 34219372)
16. Krishnaiah YS, Seetha Devi A, Nageswara Rao L, Bhaskar Reddy PR, Karthikeyan RS, Satyanarayana V. 2001. Guar gum as a carrier for colon specific delivery; influence of metronidazole and tinidazole on in vitro release of albendazole from guar gum matrix tablets. J Pharm Pharm Sci 4:235-243. (Pubitemid 34305599)
17. Lee JS, Jung YJ, Kim YM. 2001. Synthesis and evaluation of N-acyl-2-(5-fluorouracil-1-yl)-D,L-glycine as a colon-specific prodrug of 5-fluorouracil. J Pharm Sci 90:1787-1794. (Pubitemid 33062599)
18. Kim H, Kong H, Choi B, Yang Y, Kim Y, Lim MJ, Neckers L, Jung Y. 2005. Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease. Pharm Res 22:1499-1509. (Pubitemid 41215890)
19. Akao T, Terasawa T, Hiai S, Kobashi K. 1992. Inhibitory effects of glycyrrhetic acid derivatives on 11 beta- and 3 alpha-hydroxysteroid dehydrogenases of rat liver. Chem Pharm Bull (Tokyo) 40:3021-3024. (Pubitemid 23021873)
20. Kinouchi T, Ohnishi Y. 1983. Purification and characterization of 1-nitropyrene nitroreductases from Bacteroides fragilis. Appl Environ Microbiol 46:596-604.
21. Lee J, Rho J, Yang Y, Kong H, Jung Y, Kim Y. 2007. Synthesis and in vitro evaluation of N-nicotinoylglycyl-2-(5-fluorouracil-1-yl)-D,L-glycine as a colonspecific prodrug of 5-fluorouracil. J Drug Target 15:199-205. (Pubitemid 46562632)
22. Jung YJ, Doh MJ, Kim IH, Kong HS, Lee JS, Kim YM. 2003. Prednisolone 21-sulfate sodium: A colon-specific pro-drug of prednisolone. J Pharm Pharmacol 55:1075-1082.
23. Friend DR, Chang GW. 1985. Drug glycosides: Potential prodrugs for colon-specific drug delivery. J Med Chem 28:51-57. (Pubitemid 15156296)
24. Jung YJ, Lee JS, Kim YM. 2000. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid. J Pharm Sci 89:594-602.
25. Jain A, Gupta Y, Jain SK. 2006. Azo chemistry and its potential for colonic delivery. Crit Rev Ther Drug Carrier Syst 23:349-400. (Pubitemid 46524107)